Eyepoint, Inc.
A biopharmaceutical company that treats serious eye diseases with tiny, long-lasting implants placed in the eye. Its Durasert technology delivers steady doses of medication over months, powering products like YUTIQ for uveitis and DEXYCU for inflammation after cataract surgery. Founded in 1987 and long known as pSivida Corporation, it renamed itself EyePoint in 2018 after buying Icon Bioscience — the name a nod to its single-minded focus on the eye.